Product Information
OXAZEPAM 10 MG CAPSULE is a generic product labeled by Actavis Pharma, Inc., priced at $0.7247 per EA under NDC 00228206710. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Apr 14, 1988. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00228206710
Classification
Generic
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA072253FDA Approved
4/14/1988
TE Code
AB
On Market Since
1/2/2007
Pharmacological Classes
Price Statistics
The NADAC for OXAZEPAM 10 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 6.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7247 per EA |
|---|---|
| All-time high | $0.9352 (Jan 13, 2021) |
| All-time low | $0.5167 (Jun 22, 2016) |
| 52-week high | $0.8454 |
| 52-week low | $0.6884 |
| Median price | $0.7554 |
| Average price | $0.7641 |
| Largest weekly change | +42.0% (Jul 21, 2021) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Oxazepam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXAZEPAM 10 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for OXAZEPAM 10 MG CAPSULE, manufactured by Actavis Pharma, Inc., is $0.7247 per EA (NDC 00228206710), effective Sep 30, 2026.
How has the price of OXAZEPAM 10 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for OXAZEPAM 10 MG CAPSULE has declined 6.9%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for OXAZEPAM 10 MG CAPSULE?
Since Nov 28, 2013, the NADAC for OXAZEPAM 10 MG CAPSULE has ranged from a low of $0.5167 (Jun 22, 2016) to a high of $0.9352 (Jan 13, 2021), with a median of $0.7554 per EA.
Are there cheaper alternatives to OXAZEPAM 10 MG CAPSULE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OXAZEPAM 10 MG CAPSULE, is $0.6695 per EA — about 8% below OXAZEPAM 10 MG CAPSULE.
Who manufactures OXAZEPAM 10 MG CAPSULE?
OXAZEPAM 10 MG CAPSULE (NDC 00228206710) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.